Recently, the Department of Industry and Information Technology of Anhui Province unveiled the list of Anhui Provincial Specialized, Refined, Differential and Innovative SMEs for 2025. Relying on its dedicated cultivation in biomedical intermediates, refined enterprise management and continuous technological innovations, Tongling Jingke Biotechnology Co., Ltd. has successfully passed the official accreditation! This marks another important honor following its qualification as a National High-tech Enterprise, testifying that the company’s comprehensive competitiveness in its niche segment has gained authoritative official recognition.
Founded in December 2019 and situated in Tongling Economic & Technological Development Zone, Tongling Jingke serves as the core manufacturing base under Anhui Jingke Biotechnology Co., Ltd. Focused on the R&D and production of biomedical intermediates as an enzyme catalysis & chemical synthesis hub, the firm has built up a bio-based production line for D-p-hydroxyphenylglycine. It adopts self-developed heterogeneous synthesis technology for D-p-hydroxyphenylglycine featuring mild reaction conditions, low pollution, reduced energy consumption and shortened production procedures, with full independent intellectual property rights over the core technologies.
Benefiting from breakthroughs in synthetic biology, Tongling Jingke’s D-p-hydroxyphenylglycine and methyl D-p-hydroxyphenylglycine deliver superior product quality compared with mainstream domestic chemical synthesis routes. Guided by the development philosophy of specialization, refinement, differentiation and innovation, the company keeps scaling up technological innovation and commercialization of research achievements, consolidating its leading edge in antibiotic intermediates. Meanwhile, its eco-friendly production processes help advance the national dual-carbon goals and fuel high-quality advancement of the biomedical industry.
Being listed as an Anhui Provincial Specialized, Refined, Differential and Innovative SME is an official endorsement of Tongling Jingke’s technical prowess and professional competence as well as a fresh starting point for future growth. Going forward, the company will take this opportunity to expedite R&D of the third-generation manufacturing process for D-p-hydroxyphenylglycine and deepen partnerships with clients at home and abroad to further strengthen its advantages within antibiotic intermediate sector. The group will steadily increase R&D investment to build itself into a top-tier domestic synthetic biology enterprise and contribute Jingke’s strengths to innovative development across the whole biomedical industry.
